An update on developments at Nobelpharma.

C Holmberg

Home/Archive/PubMed

PubMed · 8054229

An update on developments at Nobelpharma.

C Holmberg

View original source ↗Export metadata ↓

Abstract

At Nobelpharma there is a strong belief in clinical trials; the way products function should always be documented before those products are introduced to the market. The safety of the patient must not be jeopardised. Now, Nobelpharma introduces a new system on documentation of new products, similar to the one used in the pharmaceutical industry. In its clinical studies, Nobelpharma collaborates with some 175 clinics all over the world. At present, some 40 scientific studies are in progress, involving around 1500 patients and 40,000 fixtures. The current R&D plan of Nobelpharma consists of, among others, the following four areas: 1. Improved technique and function including research on improved fit and methods for measuring fit. 2. Simplified surgery, where the self-tapping fixture and a new surgical kit are important products. 3. Reduced contra-indications, mainly concentrating on the upper jaw, with contra-indications caused by resorbed bone or poor bone quality. 4. Obtaining increased understanding of biomechanical aspects. Further research to increase biomechanical understanding and, in the longer term, to adapt components and forms of treatment to produce the optimum biomechanical system.

Explore related subjects

Clinical Trials as Topic Dental Implantation, Endosseous Dental Implants Dental Prosthesis Design Documentation Humans Organizational Policy Research Design Technology, Dental Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

C Holmberg. 1993. An update on developments at Nobelpharma.. https://pubmed.ncbi.nlm.nih.gov/8054229/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

On the exact interval estimation for the difference in paired areas under the ROC curves.

An important measure for comparison of accuracy between two diagnostic procedures is the difference in paired areas under the receiver operating characteristic (ROC) curves. Non-parametric and maximum likelihood methods have been proposed for interval estimation for the difference in paired areas under ROC curves. However, these two methods are asymptotic procedures and their performance in finite sample sizes has not been thoroughly investigated. We propose to use the concept of generalized pivotal quantities (GPQs) to construct an exact confidence interval for the difference in paired areas under ROC curves. A simulation study is conducted to empirically investigate the probability coverage and expected length of the three methods for various combinations of sample sizes, values of the area under the ROC curve and correlations. Simulation results demonstrate that the exact confidence interval based on the concept of GPQs provides not only sufficient probability coverage but also reasonable expected length. Numerical examples using published data sets illustrate the proposed method.

Clinical Trials as Topic↗

PubMed2007

An efficient test for the analysis of dichotomized variables when the reliability is known.

A difference in an outcome variable between the treatment groups in a trial does not necessarily mean that there is a difference in the number of patients who experience relevant improvement on that variable. When the relevant improvement corresponds with an outcome or change in outcome that exceeds a certain threshold, the outcome variable can be dichotomized. A responder is a patient whose outcome exceeds the threshold. Comparisons can be made between the number of responders in the two treatment groups using logistic regression, or some other method to evaluate binary outcomes. An important disadvantage of this approach is the loss of power. In general, it is more efficient to test the difference between the mean values. We developed a statistical test that compares response rates for a dichotomized variable. It requires that an estimate of the reliability of the outcome variable is available. Simulations showed that the test was valid and robust over a wide range of distributions and sample sizes. The power was greater than the power of a chi(2) test, which would enable substantial reduction in the sample size.

Clinical Trials as Topic↗

PubMed2007

Sample size determination for logistic regression revisited.

There is no consensus on the approach to compute the power and sample size with logistic regression. Some authors use the likelihood ratio test; some use the test on proportions; some suggest various approximations to handle the multivariate case. We advocate the use of the Wald test since the Z-score is routinely used for statistical significance testing of regression coefficients. The null-variance formula became popular from early studies, which contradicts modern software, which utilizes the method of maximum likelihood estimation (MLE), when the variance of the MLE is estimated at the MLE, not at the null. We derive general Wald-based power and sample size formulas for logistic regression and then apply them to binary exposure and confounder to obtain a closed-form expression. These formulas are applied to minimize the total sample size in a case-control study to achieve a given power by optimizing the ratio of controls to cases. Approximately, the optimal number of controls to cases is equal to the square root of the alternative odds ratio. Our sample size and power calculations can be carried out online at www.dartmouth.edu/ approximately eugened.

Clinical Trials as Topic↗